Afternoon Market Losers

Synta Pharmaceuticals (NASDAQ: SNTA ) is down 32.32% to $4.99 after Synta reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of Ganetespib in second-line non-small cell lung cancer. Infinity Pharmaceuticals (NASDAQ: INFI ) dropped 26.10% to 19.92 on Phase 1 data. Affymax (NASDAQ: AFFY ) dropped 19.23%